Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Myocardial Infarction

ClinicalTrials.gov lists 2,989 trials for Myocardial Infarction or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 64.

MeSH D009203 Cardiovascular Diseases C14 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 52 Phase 1/2 Phase 1/2 43 Phase 2 Phase 2 182 Phase 2/3 Phase 2/3 49 Phase 3 Phase 3 260 Phase 4 Phase 4 341 Not applicable Not applicable 869 Observational Observational 1,190 Phase 1 Phase 1 52 Phase 1/2 Phase 1/2 43 Phase 2 Phase 2 182 Phase 2/3 Phase 2/3 49 Phase 3 Phase 3 260 Phase 4 Phase 4 341 Not applicable Not applicable 869 Observational Observational 1,190

Trials per phase (log scale)

1 more section with rows

1,956 of the 2,989 trials are tagged with Myocardial Infarction itself; the rest are tagged with a narrower condition beneath it.

Get the Myocardial Infarction report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Myocardial Infarction trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 163

1990: 2 trials (Observational 2) 1991: 7 trials (Observational 7) 1992: 5 trials (Observational 2, Phase 3 3) 1993: 4 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 1) 1994: 8 trials (Observational 6, Phase 3 2) 1995: 12 trials (Observational 9, Phase 3 3) 1996: 2 trials (Phase 4 1, Phase 3 1) 1997: 9 trials (Observational 6, Not applicable 1, Phase 3 2) 1998: 12 trials (Observational 9, Phase 3 3) 1999: 13 trials (Observational 6, Phase 4 3, Phase 3 3, Phase 2 1) 2000: 14 trials (Observational 7, Not applicable 3, Phase 3 4) 2001: 26 trials (Observational 13, Not applicable 4, Phase 4 4, Phase 3 4, Phase 2/3 1) 2002: 21 trials (Observational 6, Not applicable 2, Phase 4 4, Phase 3 5, Phase 2 2, Phase 1 2) 2003: 57 trials (Observational 20, Not applicable 8, Phase 4 8, Phase 3 10, Phase 2/3 1, Phase 2 7, Phase 1/2 2, Phase 1 1) 2004: 47 trials (Observational 17, Not applicable 6, Phase 4 10, Phase 3 5, Phase 2/3 2, Phase 2 5, Phase 1/2 1, Phase 1 1) 2005: 64 trials (Observational 13, Not applicable 11, Phase 4 12, Phase 3 14, Phase 2/3 3, Phase 2 5, Phase 1/2 2, Phase 1 4) 2006: 75 trials (Observational 22, Not applicable 10, Phase 4 15, Phase 3 10, Phase 2/3 3, Phase 2 9, Phase 1 6) 2007: 83 trials (Observational 31, Not applicable 16, Phase 4 15, Phase 3 5, Phase 2/3 5, Phase 2 7, Phase 1/2 2, Phase 1 2) 2008: 75 trials (Observational 18, Not applicable 14, Phase 4 7, Phase 3 13, Phase 2/3 8, Phase 2 8, Phase 1/2 3, Phase 1 4) 2009: 86 trials (Observational 23, Not applicable 22, Phase 4 17, Phase 3 7, Phase 2/3 4, Phase 2 10, Phase 1/2 1, Phase 1 2) 2010: 95 trials (Observational 41, Not applicable 21, Phase 4 11, Phase 3 12, Phase 2 5, Phase 1/2 4, Phase 1 1) 2011: 122 trials (Observational 42, Not applicable 28, Phase 4 21, Phase 3 11, Phase 2/3 3, Phase 2 9, Phase 1/2 6, Phase 1 2) 2012: 104 trials (Observational 42, Not applicable 31, Phase 4 13, Phase 3 7, Phase 2 8, Phase 1/2 2, Phase 1 1) 2013: 102 trials (Observational 38, Not applicable 34, Phase 4 9, Phase 3 11, Phase 2 7, Phase 1/2 1, Phase 1 2) 2014: 125 trials (Observational 53, Not applicable 30, Phase 4 22, Phase 3 10, Phase 2/3 2, Phase 2 7, Phase 1 1) 2015: 136 trials (Observational 55, Not applicable 34, Phase 4 19, Phase 3 9, Phase 2/3 1, Phase 2 11, Phase 1/2 3, Phase 1 4) 2016: 127 trials (Observational 48, Not applicable 50, Phase 4 15, Phase 3 6, Phase 2/3 1, Phase 2 4, Phase 1/2 3) 2017: 142 trials (Observational 55, Not applicable 50, Phase 4 23, Phase 3 4, Phase 2/3 2, Phase 2 6, Phase 1/2 1, Phase 1 1) 2018: 148 trials (Observational 66, Not applicable 47, Phase 4 19, Phase 3 6, Phase 2/3 2, Phase 2 7, Phase 1/2 1) 2019: 143 trials (Observational 67, Not applicable 49, Phase 4 8, Phase 3 9, Phase 2/3 1, Phase 2 6, Phase 1 3) 2020: 154 trials (Observational 74, Not applicable 47, Phase 4 11, Phase 3 9, Phase 2/3 1, Phase 2 9, Phase 1/2 2, Phase 1 1) 2021: 161 trials (Observational 63, Not applicable 51, Phase 4 18, Phase 3 16, Phase 2/3 3, Phase 2 7, Phase 1/2 3) 2022: 161 trials (Observational 67, Not applicable 61, Phase 4 14, Phase 3 6, Phase 2 8, Phase 1/2 2, Phase 1 3) 2023: 163 trials (Observational 64, Not applicable 71, Phase 4 11, Phase 3 9, Phase 2 5, Phase 1 3) 2024: 143 trials (Observational 62, Not applicable 56, Phase 4 6, Phase 3 7, Phase 2/3 1, Phase 2 8, Phase 1/2 1, Phase 1 2) 2025: 146 trials (Observational 61, Not applicable 49, Phase 4 10, Phase 3 9, Phase 2/3 1, Phase 2 10, Phase 1/2 3, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 143
2025 146
2024 143
2023 163
2022 161
2021 161
2020 154
2019 143
2018 148
2017 142

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 160 trials starting in 2026 and about 150 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 219 trials still running at the 2026-10-09 snapshot; registered median of 28 months across 1,631 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Myocardial Infarction trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 52
Phase 1/2 43
Phase 2 182
Phase 2/3 49
Phase 3 260
Phase 4 341
Not applicable 869
Observational 1,190
Expanded access 3

How many Myocardial Infarction trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 138
Recruiting 353
Enrolling by invitation 18
Active, not recruiting 103
Available 2

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Myocardial Infarction trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 64
AstraZeneca 18

Which drugs are being tested for Myocardial Infarction? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
ATORVASTATIN 22
Abciximab 16
BMS-512148 15
LOVENOX 14
Rivaroxaban 14

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Ticagrelor (Brilique) 90 63
Clopidogrel 75 50
EC Aspirin 35
Prasugel 26
Colchicines 22

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Myocardial Infarction trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Other 16,717 6
MVE 6,060 1
Pneumonia 2,938 52
Hospitalization 1,855 2
Angina pectoris 1,629 38

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Myocardial Infarction? (8,278)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Diagnostic and prognostic utility of endocan in suspected myocardial infarction: an international cohort study. Clinica chimica acta; international journal of clinical chemistry 2026 Yes
PRevention of sudden cardiac death aFter myocardial infarction by defibrillator implantation: Design and rationale of the PROFID EHRA randomized clinical trial. American heart journal 2026 Yes
Intra-aortic balloon pump implantation in early-stage cardiogenic shock reduces 30-day mortality in patients with ventricular septal defect following myocardial infarction. International journal of cardiology 2026 Yes
Design and Analytical Evaluation of an Immunoassay for Long Forms of Cardiac Troponin T. The journal of applied laboratory medicine 2026 Yes
Clinical Performance of a Novel Point-of-Care High-Sensitivity Cardiac Troponin I Assay. The journal of applied laboratory medicine 2026 Yes

Showing 5 of 8,278 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages